Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
暂无分享,去创建一个
[1] E. Lawitz,et al. 1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS , 2012 .
[2] John McNally,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.
[3] Todd M. Allen,et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.
[4] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[5] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[6] C. Stedman,et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.
[7] R. Fontana,et al. Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] M. Otto,et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.
[9] K. Reddy,et al. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection , 2013, Expert opinion on investigational drugs.
[10] E. Schiff,et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.
[11] C. Stedman,et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. , 2014, Gastroenterology.
[12] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[13] C. Stedman,et al. 14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY , 2013 .
[14] K. Kowdley,et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. , 2013, Journal of hepatology.
[15] K. Reddy,et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. , 2013, The Lancet. Infectious diseases.
[16] J. Murray,et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. , 2013, Gastroenterology.
[17] T. Marbury,et al. 1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977 , 2012 .
[18] D. Samuel,et al. Autoimmune acute liver failure , 2011, Hepatology.
[19] F. Carrat,et al. 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) , 2013 .
[20] M. Otto,et al. Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus , 2012, Antimicrobial Agents and Chemotherapy.
[21] M. Otto,et al. Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.
[22] T. Hassanein,et al. 848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR , 2013 .
[23] A. Lok,et al. 1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) , 2013 .
[24] T. Hassanein,et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.